首页 | 本学科首页   官方微博 | 高级检索  
     

鼻咽癌免疫治疗进展
引用本文:周凤格,易俊林. 鼻咽癌免疫治疗进展[J]. 中华放射肿瘤学杂志, 2021, 30(4): 407-412. DOI: 10.3760/cma.j.cn113030-20200205-00046
作者姓名:周凤格  易俊林
作者单位:国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科 100021
摘    要:鼻咽癌是一种与EB病毒(EBV)感染密切相关的恶性肿瘤。鼻咽癌在接受现代调强放疗技术为主的综合治疗后,疗效得到进一步提高。提高高危患者和复发/远处转移鼻咽癌(R/M-NPC)患者的疗效成为治疗的主要目标。近年来,免疫治疗在肿瘤治疗领域不断取得进步。随着对EBV抗原及免疫检查点抑制剂的研究,免疫治疗在R/M-NPC治疗中...

关 键 词:鼻咽癌  EB病毒  免疫治疗  免疫检查点抑制剂
收稿时间:2020-02-05

Research progress on immunotherapy for nasopharyngeal carcinoma
Zhou Fengge,Yi Junlin. Research progress on immunotherapy for nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 407-412. DOI: 10.3760/cma.j.cn113030-20200205-00046
Authors:Zhou Fengge  Yi Junlin
Affiliation:Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract:Nasopharyngeal carcinoma (NPC) is a malignant carcinoma that is closely associated with Epstein Barr virus (EBV) infection. After the comprehensive treatment based on modern intensity-modulated radiation therapy, the oncological outcomes can be further improved. The main target of treatment is to increase the efficacy ofpatients with high risk and recurrent/metastatic (R/M) NPC.Recently, continuous progress has been made in the application of immunotherapy in the field of cancer treatment. Based on the accumulated knowledge on EBV antigen and immune checkpoint inhibitors, significant progress has been made in use of immunotherapy in treating R/M-NPC. Immunotherapy combined with radiotherapy or chemoradiotherapy will become the hot spot in the clinical management of patients with newly-diagnosed high-risk NPC.
Keywords:Nasopharyngeal carcinoma  Epstein Barr virus  Immunotherapy  Immune checkpoint inhibitor  
本文献已被 维普 等数据库收录!
点击此处可从《中华放射肿瘤学杂志》浏览原始摘要信息
点击此处可从《中华放射肿瘤学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号